바로가기메뉴

본문 바로가기 주메뉴 바로가기

The Proportion of Rifabutin-susceptible Strains among Rifampicin-resistant Isolates and Its Specific rpoB Mutations

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2005, v.59 no.3, pp.257-265






  • Downloaded
  • Viewed

Abstract

keywords
Rifabutin, MDR-TB, rpoB mutation, Rifabutin, MDR-TB, rpoB mutation

Reference

1.

Telenti A, (1993) Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis,

2.

Michison DA, (1986) Influence of initial drug resistance on the response to short-course chemotherapy in pulmonary tuberculosis,

3.

McGregor MM, (1996) Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis,

4.

Telenti A, (1997) Genetics of drug resistance in tuberculosis ,

5.

Dickinson JM, (1987) In vitro activity of new rifamycins against rifampicin-resistant M.tuberculosis and MAIS-complex mycobacteria,

6.

Hong Kong Chest Service/British Medical Research Council, (1992) A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid,streptomycin and rifampicin,

7.

Blumberg HM, (2003) American Thoracic Society/Centers for Disease Control and Prevention/ Infectious Diseases Society of America:treatment of tuberculosis,

8.

Kim SJ, (1997) Drug resistant tuberculosis in Korea,1994,

9.

Kox LF, (1995) PCR assay based on DNA coding for 16S rRNA for detection and identification of mycobacteria in clinical samples,

10.

Nolan CM, (1995) Evolution of rifampin resistance in human immunodeficiency virus-associated tuberculosis,

11.

Goble M, (1993) Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin,

12.

Grassi C, (1996) Use of rifabutin in the treatment of pulmonary tuberculosis,

13.

Dickinson JM, (1987) In vitro activity of new rifamycin against rifampicin-resistant M.tuberculosis and MAIS-complex mycobacteria,

14.

Yang B, (1998) Relationship between antimycobacterial activities of rifampicin,rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis,

15.

Williams DL, (1998) Contribution of rpoB mutation to development of rifamycin cross-resistance in Mycobacterium tuberculosis,

16.

Cavusoglu C, (2004) In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations,

17.

Yuen LK, (1999) Bacteriological and molecular analysis of rifampin-resistant Mycobacterium tuberculosis strains isolated in Australia,

18.

Bodmer T, (1995) Mutation position and type of substitution in the β-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant Mycobacterium tuberculosis,

19.

Moghazeh SL, (1996) Comparative antimycobacterial activities of rifampin,rifapentine,and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations,

Tuberculosis & Respiratory Diseases